IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR

Oncogene

Volumn 30, Issue 20, 2011, Pages 2345-2355

  Rojas, A ^a   Liu, G ^a   Coleman, I ^b   Nelson, P S ^b   Zhang, M ^a   Dash, R ^c   Fisher, P B ^c   Plymate, S R ^a   Wu, J D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EMT; IGF IR; IL 6; prostate; STAT3; tumorigenesis

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NERVE CELL ADHESION MOLECULE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; MICROENVIRONMENT; MOUSE; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

AUTOCRINE COMMUNICATION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTERLEUKIN-6; MALE; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 79956126860     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.605     Document Type: Article

References (46)

1. Al-Shanti N, Saini A, Faulkner SH, Stewart CE. (2008). Beneficial synergistic interactions of TNF-alpha and IL-6 in C2 skeletal myoblasts-potential cross-talk with IGF system. Growth Factors 26: 61-73. (Pubitemid 351584058)
2. Ara T, Declerck YA (2010). Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231.
3. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. (1994). Tumorigenicity of SV40T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer 58: 721-729. (Pubitemid 24279437)
4. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. (2009). Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 9: 419-426.
5. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501. (Pubitemid 39370505)
6. Berger T, Cheung CC, Elia AJ, Mak TW (2010). Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci USA 107: 2995-3000.
7. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al. (2003). A fully human monoclonal antibody to the insulinlike growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921. (Pubitemid 38064071)
8. Coe KJ, Jia Y, Ho HK, Rademacher P, Bammler TK, Beyer RP et al. (2007). Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chem Res Toxicol 20: 1277-1290. (Pubitemid 47548296)
9. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J et al. (2009). Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144.
10. Corcoran NM, Costello AJ. (2003). Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 91: 545-553. (Pubitemid 36570580)
11. Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL et al. (2001). Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142: 21-27. (Pubitemid 32183661)
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269. (Pubitemid 46486616)
13. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara Jr PN, Van Veldhuizen Jr PJ et al (2010). Clinical correlative results of SWOG S0354 a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16: 3028-3034.
14. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF et al. (2009). Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 182: 1621-1627.
15. Freedland SJ, Platz EA. (2007). Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29: 88-97. (Pubitemid 47229642)
16. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113.
17. Grivennikov S, Karin M. (2008). Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9. (Pubitemid 350309747)
18. Haverkamp J, Charbonneau B, Ratliff TL. (2008). Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 103: 1344-1353. (Pubitemid 351490705)
19. Irigaray P, Newby JA, Lacomme S, Belpomme D. (2007). Overweight/ obesity and cancer genesis: more than a biological link. Biomed Pharmacother 61: 665-678. (Pubitemid 350236686)
20. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y et al. (2009). aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcrip-tional activation of interleukin-6. Proc Natl Acad Sci USA 106: 16369-16374.
21. Kang Y, Massague J. (2004). Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279. (Pubitemid 39061108)
22. Karnoub AE, Weinberg RA. (2008). Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531. (Pubitemid 351881844)
23. Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. (2009). Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 16: 161-167.
24. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. (2005). Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 108: 1-11. (Pubitemid 40052280)
25. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H et al. (2000). Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706. (Pubitemid 30482107)
26. O'Malley RL, Taneja SS. (2006). Obesity and prostate cancer. Can J Urol 13(Suppl 2): 11-7.
27. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. (2007). The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol 25: 477-489.
28. Rosen DG, Yang G, Bast Jr RC, Liu J. (2006). Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol 407: 660-676.
29. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. (2007). IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13: 5549s-5555s. (Pubitemid 47510386)
30. Santer FR, Malinowska K, Culig Z, Cavarretta IT (2010). Inter-leukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 17: 241-253.
31. Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH et al. (1999). Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 19: 3816-3828. (Pubitemid 29193841)
32. Su ZZ, Sarkar D, Emdad L, Duigou GJ, Young CS, Ware J et al. (2005). Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci USA 102: 1059-1064. (Pubitemid 40170725)
33. Su ZZ, Shi Y, Fisher PB. (1997). Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc Natl Acad Sci USA 94: 9125-9130.
34. Su Z, Shi Y, Fisher PB. (2000). Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 19: 3411-3421. (Pubitemid 30479336)
35. Su Z, Shi Y, Friedman R, Qiao L, McKinstry R, Hinman D et al. (2001). PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells. Nucleic Acids Res 29: 1661-1671. (Pubitemid 32427846)
36. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N et al. (2009). Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28: 2940-2947.
37. Sutcliffe S, Platz EA. (2007). Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol 25: 242-249. (Pubitemid 46680518)
38. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. (2007). Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97: 378-383. (Pubitemid 47196744)
39. Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
40. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
41. Traynor P, McGlynn LM, Mukhergee R, Grimsley SJ, Bartlett JM, Edwards J. (2008). An increase in N-Ras expression is associated with development of hormone refractory prostate cancer in a subset of patients. Dis Markers 24: 157-165. (Pubitemid 352038624)
42. Tusher VG, Tibshirani R, Chu G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121. (Pubitemid 32397092)
43. Werner H, Bruchim I. (2009). The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58-71.
44. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL et al. (2009). Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 106: 3913-3918.
45. Zeisberg M, Neilson EG. (2009). Biomarkers for epithelial-mesench-ymal transitions. J Clin Invest 119: 1429-1437.
46. Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE. (2009). Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther 8: 499-508.